SAXENDA (Liraglutide) Market Size and Share Across 7MM and Competitive Landscape by DelveInsight | Key Players - Novo Nordisk

DelveInsight has released a comprehensive report titled "SAXENDA (Liraglutide) Market Forecast" offering a thorough examination and predictive insights into the SAXENDA (Liraglutide) market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The extensive report offers a thorough examination of the market potential and market share of SAXENDA (Liraglutide) in the therapeutics landscape for Obesity across the 7MM, spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of SAXENDA (Liraglutide), encompassing both clinical and commercial dimensions. Key parameters such as the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.

Get a detailed overview of the SAXENDA (Liraglutide) drug and stay ahead of the competition by leveraging key insights:
https://www.delveinsight.com/report-store/saxenda-liraglutide-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

SAXENDA (Liraglutide) Drug Insights
SAXENDA, also known as Liraglutide, operates as a potent agonist for the Glucagon-like Peptide 1 (GLP-1) receptor. It serves as a supplementary treatment alongside a reduced-calorie diet and increased physical activity for the prolonged management of weight in adults. This medication is specifically recommended for individuals with an initial Body Mass Index (BMI) of 30 kg/m2 or greater, indicating obesity, or a BMI of 27 kg/m2 or greater, indicating overweight, if accompanied by at least one weight-related comorbid condition such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Additionally, it is approved for pediatric patients aged 12 years and older with a body weight exceeding 60 kg and an initial BMI corresponding to 30 kg/m2 for adults, as per international standards.

SAXENDA is typically prescribed at a daily dose of 3 mg. To minimize potential side effects, it's advisable to initiate treatment with a lower dosage of 0.6 mg per day for the first week. Subsequently, the dosage can be gradually increased on a weekly basis until reaching the target dose of 3 mg. In cases where pediatric patients experience difficulties in tolerating dose increments during the titration period, it's permissible to revert to the previous lower dosage level. Pediatric patients may undergo dose escalation for a duration of up to 8 weeks to optimize their treatment. If a 3 mg daily dose proves intolerable for pediatric patients, adjustment to a lower dose of 2.4 mg per day may be considered.

Liraglutide, an acylated human Glucagon-like Peptide-1 (GLP-1) receptor agonist, shares a remarkable 97% amino acid sequence similarity with native human GLP-1(7-37). Functionally akin to endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor linked to adenylyl cyclase activation through the stimulatory G-protein, Gs. However, while natural GLP-1 has a fleeting half-life of merely 1.5-2 minutes due to degradation by ubiquitous enzymes like Dipeptidyl Peptidase 4 (DPP-4) and Neutral Endopeptidases (NEP), liraglutide exhibits remarkable stability. It is resistant to metabolic breakdown by both peptidases, boasting an extended plasma half-life of thirteen hours after subcutaneous injection. This prolonged pharmacokinetic profile of liraglutide enables once-daily dosing and is attributed to several factors. Firstly, liraglutide's tendency to self-associate delays its absorption. Secondly, it binds to plasma proteins, further extending its circulation time. Lastly, its resistance to degradation by DPP-4 and NEP contributes significantly to its sustained presence in the bloodstream. These unique properties make liraglutide a promising option for efficient and convenient management of conditions requiring GLP-1 receptor activation.

GLP-1 acts as a natural modulator of both appetite and calorie consumption, with its receptor distributed across various brain regions implicated in the regulation of hunger. Animal research has shown that when liraglutide is administered peripherally, it penetrates specific brain areas responsible for appetite control, notably the hypothalamus. While liraglutide triggers the activation of neurons within these appetite-regulating brain regions, pinpointing the exact areas that mediate its influence on appetite in rats has proven elusive.

Explore key clinical, commercial, and regulatory milestones associated with SAXENDA (Liraglutide) by visiting:
https://www.delveinsight.com/sample-request/saxenda-liraglutide-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Key Highlights of the SAXENDA (Liraglutide) Market Report
• The report includes a projected assessment of SAXENDA (Liraglutide) sales for Obesity up to the year 2032.
• The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of Obesity.
• The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on SAXENDA (Liraglutide) for Obesity.

Why SAXENDA (Liraglutide) Market Report?
• The projected market data for SAXENDA (Liraglutide) in the context of Obesity will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of SAXENDA (Liraglutide), aiding in strategic planning and decision-making processes within the therapeutic domain.
• A comprehensive market forecast for SAXENDA (Liraglutide) will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug's positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.
• The report additionally offers future market assessments for the SAXENDA (Liraglutide) market in the field of Obesity across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of Obesity. This multifaceted approach ensures a comprehensive understanding of the SAXENDA (Liraglutide) market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.
• Conducting a thorough market forecast for SAXENDA (Liraglutide) will facilitate a detailed analysis of the drug's clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of SAXENDA (Liraglutide).

Visit and Explore How SAXENDA (Liraglutide) Is Set to Dominate the Obesity Therapeutic Market:
https://www.delveinsight.com/sample-request/saxenda-liraglutide-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Contents of the Report
1. Report Introduction
2. SAXENDA (Liraglutide) Overview in Obesity
3. Competitive Landscape (Key Assessment of the Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies Analysis)
5. SAXENDA (Liraglutide) Market Assessment
6. SWOT Analysis
7. Analysts' Views
8. Appendix
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
* The final table of contents may be subject to change based on user demand.

Request the Sample PDF to Learn More About the Key Offerings of the SAXENDA (Liraglutide) Market Report @
https://www.delveinsight.com/sample-request/saxenda-liraglutide-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

----------------------------------------------------------------------------------------------------------------------------------

Other Related Reports By DelveInsight
Obesity Pipeline Insight
DelveInsight's "Obesity Pipeline Insight" report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the Obesity Therapeutics market include Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Novartis, Novo Nordisk, Pfizer, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Saniona, Shionogi, Sigrid Therapeutics, Sun Pharmaceutical Industries, Terns Pharmaceuticals, Tonix Pharmaceuticals, Versanis Bio, Viking Therapeutics, Zealand Pharma, Hanmi Pharmaceutical, Innovent Biologics, Kallyope, Gannex Pharma, Eurofarma, and others. Visit & explore how the Obesity therapeutics pipeline is evolving, at:
https://www.delveinsight.com/report-store/obesity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.